Clinical trials: Dementia, Alzheimer's Type
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.
Dementia, Alzheimer Disease
Community-based Brain Health Program to Address Dementia Risk
This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions.
- Trial name
- C-BBHP (NCT05529706)
- Testing
- Brain Health Program
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Posit Science Corporation
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Stress, Carer Stress Syndrome
Tailored Health Self-Management Interventions for Highly Distressed Caregivers: Family Members of Persons With Dementia
How do different health self-management interventions (resourcefulness training or biofeedback training) compare to usual care (dementia education) in affecting the health risks, and physical and mental health, of family…
- Conditions
- Stress, Carer Stress Syndrome, Dementia, Alzheimer Disease
- Trial name
- NCT04247347
- Testing
- Biofeedback Training, Dementia Education, Resourcefulness Training
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Alzheimer Disease
Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
Lymphaticovenous anastomosis (LVA) is a microsurgical technique that involves anastomosing fine lymphatic vessels with adjacent veins to reestablish lymphatic drainage pathways.
- Trial name
- NCT07294885
- Testing
- deep cervical lymphaticovenous anastomosis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- General Hospital of Shenyang Military Region
Alzheimer Disease, Mild Cognitive Impairment
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
This study seeks to better understand how older adult aging-in-place/long term care decision making and implementation is impacted by age-related changes (e.g.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
- Trial name
- PYL (NCT03960476)
- Testing
- PlanYourLifespan.org
- Where
- United States
- Volunteers
- 293 people
- Sponsor
- Northwestern University
Alzheimer's Disease, Parkinson's Disease
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
The aim of this study is to compare personality and social cognition changes, including emotion detection and self-awareness, and neuroanatomical correlates in patients, and how that affects the caregiver-patient relationship.
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Frontotemporal Lobar Degeneration
- Trial name
- NCT02964611
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Alzheimer's Disease
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical…
- Trial name
- NCT01093664
- Testing
- AFFITOPE AD02
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Affiris AG
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
- Trial name
- Reτain (NCT06544616)
- Testing
- JNJ-64042056
- Where
- 90 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Neurodegenerative Disease, Alzheimer s Disease
[18F]NIDF PET Imaging in Tau-related Diseases
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body.
- Conditions
- Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
- Trial name
- NCT07306598
- Where
- 3 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Alzheimer Disease
An Objective Assessment Tool for Evaluating Functioning in Older Adults
The Investigators are seeking your consent to participate in research investigating the development of a mobile application that enhances physical and cognitive assessments.
- Trial name
- SPPB++ (NCT06489847)
- Testing
- SPPB++ Application
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
Oxaloacetate Pharmacokinetics and Safety
By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any…
- Trial name
- NCT02063308
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Russell Swerdlow, MD
Dementia Alzheimers, Dementia With Lewy Bodies
Dementias and Microbiota Composition: Is Possible to Revert the Dementia Symptoms Reverting the Microbiota Composition?
Dementia is the major cause of disability and dependency among older adults worldwide affecting memory, cognitive abilities and behavior, interfering with one's ability to perform daily lives activities.
- Conditions
- Dementia Alzheimers, Dementia With Lewy Bodies, Parkinson Disease Dementia, Dementia Frontotemporal
- Trial name
- DEM-BIOTA (NCT05943925)
- Testing
- No intervention, Probiotic supplement
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Rovira i Virgili
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
Bumetanide in Patients With Alzheimer's Disease
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension.
- Trial name
- BumxAD (NCT06052163)
- Testing
- Bumetanide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD)…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT00249158
- Testing
- Risperidone
- Volunteers
- 344 people
- Sponsor
- Janssen-Cilag Pty Ltd